Researchers have designed an antibody that targets all four serotypes of dengue, sparking hopes for the first viable dengue therapeutic
A multinational research team comprising scientists, engineers and drug developers have joined forces to develop a viable dengue therapeutic that targets all dengue serotypes. Their results, published in Cell, come as welcome news at a time were an estimated 400 million people are infected with dengue each year.
Researchers from the Singapore-MIT Alliance for Research and Technology (SMART), Duke-NUS Graduate School of Medicine (Duke-NUS), National University of Singapore (NUS) and Nanyang Technological University (NTU) have collaborated with the Massachusetts Institute of Technology (MIT) and a biotechnology company, Visterra, to develop a single treatment for all four serotypes of dengue.
The team started with a naturally occurring antibody that reacted only against limited number of types of dengue virus. Using that antibody as a scaffold, the team engineered a new antibody that reacts against all four types of dengue virus.
The engineering was made possible by computational methods developed in MIT and SMART. This was then confirmed and validated using a detailed crystal structure of the antibody-virus protein complex obtained at NTU, which also provided insights into how the antibody engaged the virus to produce the desired effect.
Using a variety of systems developed in the SMART laboratories in the Campus for Research Excellence And Technological Enterprise (CREATE) (e.g. the SMART humanised mouse model), Duke-NUS and NUS, the team then showed that this novel antibody has the potential to neutralise dengue virus and prevent signs of disease.
Another important feature of this antibody is that it acts on a part of the virus that is not normally targeted by the normal human immune response. This is important as the antibody would not need to compete with but would instead augment the overall natural immune response against dengue virus.
“This interdisciplinary, transnational team has enabled us to address this problem in unique ways,” said Professor Ram Sasisekharan, SMART principal investigator (PI) of the Infectious Diseases Interdisciplinary Research Group (ID IRG), and MIT Professor of Biological Engineering and Health Sciences & Technology, who led the team. “A single laboratory would not have the breadth of expertise to solve this problem on its own.”
“We have each been working on our own areas of interests for years,” added Associate Professor Ooi Eng Eong, deputy director of the Emerging Infectious Diseases Programme at Duke-NUS and SMART co-lead PI of ID IRG. “To be able to take what we have built over the years and put it together to solve a critical medical need, has been very rewarding personally and professionally.”
Read more: Engineered Antibody Neutralizes All Four Dengue Serotypes
The Latest on: Dengue vaccine
[google_news title=”” keyword=”dengue vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Dengue vaccine
- Japanese vaccine against dengue approved for use in Argentinaon April 27, 2024 at 5:00 pm
The vaccine, called TAK-003, is based on dengue virus 2, to which DNA from the other three serotypes is added to protect against any of the four types of dengue, it was explained.
- Dealing a knockout blow to dengueon April 27, 2024 at 3:15 pm
Bacteria-based solutions such as Wolbachia could prevent mosquitos expansion due to climate change. - PIXABAY/Filepic ...
- A vaccine against dengue in times of crisis: How, where and when?on April 26, 2024 at 8:49 pm
The drug Qdenga, which has begun to be distributed massively in Brazil, could be a useful tool against a disease on the rise in Latin America ...
- Climate change need not mean more dengue cases if cities are built better: Expertson April 26, 2024 at 3:00 am
When warmer temperatures put stress on the agriculture sector, for instance, more people may move to cities, which is exactly where the Aedes mosquito and the dengue virus thrive, with the virus ...
- Lessons for dengue vaccines from a human challenge studyon April 25, 2024 at 4:05 pm
Dengue is an acute mosquito-borne illness that is caused by four different dengue viruses (serotypes 1–4). More than half the world's population lives at risk of dengue. Among the different approaches ...
- Babies of dengue-infected pregnant women shown to be at high risk for poor health in first years of lifeon April 25, 2024 at 9:23 am
The newborns of women who had even mild dengue fever during pregnancy had a 67% and 133% greater risk of being classified as very and extremely low birth weight, respectively.
- Bali urges foreign tourists to get dengue fever vaccines amid increasing caseson April 22, 2024 at 9:30 pm
Bali advises tourists to get vaccinated against dengue fever for health. Bali Health Agency emphasizes importance for residents and visitors. Proactive measures taken amid rising cases. Indian ...
- Dengue cases top 5.2 million in the Americas as outbreak passes yearly record, PAHO sayson April 19, 2024 at 3:40 pm
Dengue cases are surging in the Americas, with cases reported topping 5.2 million as of this week, surpassing a yearly record set in 2023, according to the Pan American Health Organization (PAHO).
- Dengue Fever in Adultson April 19, 2024 at 3:24 pm
It turns out that dengue fever also attacks adults and not only attacks residents in cities, but also in villages.
- DNA vaccine against Zika performs well in tests on miceon April 18, 2024 at 9:47 am
In Brazil, researchers at the University of São Paulo (USP) and the Pernambuco division of Oswaldo Cruz Foundation (FIOCRUZ) are developing a Zika vaccine. The formulation was tested on mice and found ...
via Bing News
